On page 15, line 29, immediately following the first "ATCC #", insert --97325--.

On page 23, line 19, immediately following "#", insert --11990--.

## IN THE CLAIMS:

Please add new Claims 62-64

Please cancel Claims 43-48, 52-61

Please amend the claims as follows:

- 37. A DNA plasmid comprising an adenoviral gene fragment E4 open reading frame ORF6 operably linked to an inducible promoter.
- 38. (amended) The DNA plasmid of claim 37 wherein the inducible promoter is a promoter selected from [the] a cAMP response element binding protein regulated genes.
  - 39. (amended) The DNA plasmid of claim 38 wherein the inducible promoter is selected from [the]  $\underline{a}$  gene encoding mammalian alpha inhibin.
  - 40. (amended) The DNA plasmid of claim 38 wherein the inducible promoter is from mouse alpha inhibin.
  - 41. (amended) The DNA plasmid of claim 38 wherein the inducible promoter is selected from a drug inducible tetracycline responsive promoter.

BEST AVAILABLE COPY



- (amended) The plasmid pIK6.1 MIP( $\alpha$ ) -E4 ORF6 designated ATC # 97325.
- (amended) A packaging cell line derived from a 293 49. cell that supports the growth of a mutant adenovirus defective in replication or a recombinant adenoviral vector, wherein said adenovirus or adenoviral vector comprises a transgene and a lethal deletion or mutation in two gene regions selected [at least two deletions, at least two mutations, or at least one mutation and one deletion selected] from the group consisting of E1, E2A, E4-ORF6 early regions, and optionally a deletion of the E3 gene region [and said recombinant adenoviral vector additionally comprises a transgene that replaces any one of said deletions].
- (amended) A packaging cell line derived from a 293 cell that supports the growth of a mutant adenovirus defective in replication or a recombinant adenoviral vector, wherein said adenovirus or adenoviral vector comprises a transgene and a lethal deletion or mutation in each of adenovirus [two deletions from the] E1 and E4-ORF6 early gene regions, and optionally a deletion of the E3 region [and said recombinant adenoviral vector additionally comprises a transgene that replaces any on said deletions].

(amended) The packaging cell line derived from human embryonic kidney cells transfected with the adenovirus 5 E4 ORF6 DNA gene fragment designated ATCC CRL# 11990.